CSF1R and breast carcinoma: Similar effects have been observed in studies on oral and breast cancers; CSF-1R inhibitor monotherapy resulted in depletion of M2 macrophages and an increase in CD8- and CD4-positive T cells, despite not suppressing tumor growth [21,40,41,42].